New Guide Maps the Full Toolkit for Tracking Antigen-Specific T Cells

A sweeping comparative review published in Nature Protocols has brought order to one of immunology’s most fragmented landscapes: the bewildering array of laboratory techniques used to find, count and characterize the human T cells that recognize a specific antigen. An international consortium of more than twenty researchers, spanning academia, vaccine developers and diagnostic companies, systematically compared traditional and cutting-edge immunomonitoring methods, charting the field’s evolution from low-dimensional assays that measure a single readout to high-dimensional platforms that dissect the identity, function and receptor sequence of individual antigen-specific cells. The work arrives at a moment when vaccines, cancer immunotherapies and cellular medicines all depend on reliably measuring these rare cells, and it offers both a technical reference and a strategic framework for choosing the right tool for the right question.

T cells sit at the heart of adaptive immunity. Each one carries a T cell receptor generated by random recombination of gene segments, producing a repertoire of staggering diversity that can, in principle, recognize virtually any peptide fragment displayed on major histocompatibility complex molecules. When a T cell encounters its cognate peptide-MHC complex presented by an infected or malignant cell, it becomes activated, proliferates and executes effector functions such as cytokine secretion or direct killing. Because antigen-specific T cells typically exist at very low frequencies in peripheral blood, and because they are enormously heterogeneous in phenotype, function and receptor sequence, quantifying them accurately has challenged immunologists for decades. The new review emphasizes that no single assay can capture the full picture, and that the choice of method fundamentally shapes what a study can and cannot conclude.

The oldest approaches in the field rely on functional readouts of bulk cell populations. Lymphocyte proliferation assays, dating back to the 1970s, measure how many T cells divide in response to antigen stimulation, originally using radioactive tritiated thymidine incorporation and later shifting to fluorescent dyes such as CFSE that allow division tracking by flow cytometry. Cytotoxicity assays, most famously the chromium-51 release assay introduced in 1968, quantify the killing of labeled target cells. These methods remain informative for assessing whether a T cell population can proliferate or kill, but they provide little information about which cells are responsible, what phenotype they carry, or how they relate to protective immunity. The review notes that dye-based proliferation assays and their radioactive predecessors can differ in sensitivity for low-frequency responses, and that modern modifications preserve cell viability while enabling spectral flow cytometry analysis.

The enzyme-linked immunospot, or ELISPOT, assay transformed the field by allowing direct enumeration of individual antigen-reactive cells. Developed originally in 1983 to count antibody-secreting cells and adapted for T cell cytokines, ELISPOT detects the footprints of secreted molecules such as interferon-gamma on a membrane, with each spot corresponding to a single responding cell. Its sensitivity, relative simplicity and suitability for large clinical trials made it a workhorse of vaccine immunology, from hepatitis B studies in the 1990s through the massive COVID-19 vaccine programs, where it helped document T cell responses to BNT162b1 and booster regimens. The review highlights that decades of proficiency panels run by the Cancer Vaccine Consortium and harmonization guidelines for automated spot evaluation have made ELISPOT one of the most standardized functional assays available. Its extension, FluoroSpot, permits simultaneous detection of multiple cytokines, revealing polyfunctional response profiles that correlate more closely with protective immunity than single-cytokine counts.

Flow cytometry brought a decisive leap in information content. Intracellular cytokine staining, enabled by protein transport inhibitors such as brefeldin A, allows researchers to identify which T cells produce which cytokines while simultaneously measuring dozens of surface markers. The review traces the maturation of this approach from early two-color experiments through validated eight-color assays optimized for vaccine trials, up to contemporary spectral flow cytometry panels that approach fifty parameters. Alongside cytokine readouts, activation-induced marker assays exploit the upregulation of surface molecules such as CD154, CD137, OX40, CD25 and CD69 after antigen encounter. Because these markers appear without requiring intracellular fixation, they allow viable sorting of antigen-specific cells for downstream expansion or sequencing. The review notes that AIM assays have proven particularly valuable for detecting rare CD4 T cell responses, including those to SARS-CoV-2, that conventional cytokine assays miss, and that recent automated workflows have improved their reproducibility across laboratories.

Perhaps the most direct way to identify an antigen-specific T cell is to bind it with a soluble mimic of its ligand. Peptide-MHC multimers, introduced with tetramers in 1996, achieve this by clustering fluorescently labeled peptide-MHC complexes so that the low-affinity T cell receptor interaction becomes stable enough for detection. The review documents the steady engineering of these reagents: reversible multimers that can be stripped from cells after staining, conditional MHC ligands that allow on-demand peptide loading, dodecamers with enhanced avidity, affinity-matured class II reagents for robust CD4 staining, and combinatorial encoding schemes that pool dozens of differently labeled multimers in a single tube. DNA-barcoded multimers push the concept further, enabling screening of hundreds of specificities simultaneously by sequencing rather than fluorescence. Applied to COVID-19, malaria, celiac disease and cancer neoantigens, multimer staining provides phenotypic depth that functional assays cannot match, though it requires knowledge of the epitope and the restricting HLA allele.

High-throughput sequencing of T cell receptors has opened an entirely orthogonal window on antigen-specific immunity. Rather than interrogating function or ligand binding, repertoire sequencing catalogs the receptor sequences themselves, revealing clonal expansions, shared public clonotypes and convergent responses across individuals. The review discusses the technical challenges that once limited this approach, including biases among sequencing platforms and the difficulty of pairing alpha and beta chains, and describes solutions ranging from unique molecular identifiers to single-cell methods that link receptor sequence with transcriptome. Computational tools such as GLIPH2 and tcrdist3 cluster receptors by sequence similarity to predict shared specificity, enabling antigen discovery from repertoire data alone. The authors emphasize that sequencing reveals which clones expanded but not what they do, making it most powerful when combined with functional or phenotypic assays on the same cells.

Single-cell multiomics now fuses these dimensions. Methods that pair TCR sequencing with single-cell RNA profiling allow researchers to perform reverse phenotyping, inferring antigen specificity from receptor sequence while simultaneously reading out the transcriptional state of each cell. The review cites applications ranging from identifying SARS-CoV-2-reactive T cell signatures to distinguishing tumor-reactive from bystander clonotypes in pancreatic cancer and brain metastases. Spatial technologies extend the analysis into tissue, with imaging mass cytometry, multiplex immunohistochemistry and spatially resolved TCR sequencing mapping where specific clonotypes reside within tumors and lymphoid structures. These approaches matter because blood-based monitoring may not reflect what happens at the site of disease, and because the spatial organization of immune cells increasingly predicts immunotherapy response, as demonstrated by the clinically validated Immunoscore in colon cancer.

Underlying all of these technologies is a set of preanalytical variables that the review treats with unusual rigor. How blood is drawn, how peripheral blood mononuclear cells are isolated, how samples are cryopreserved and thawed, which culture medium and serum are used, and how long samples sit before stimulation can each swing assay results dramatically. Validation studies have shown that optimized PBMC processing enhances detected response rates in HIV vaccine trials, that serum-free media support consistent ELISPOT performance, and that suboptimal freezing conditions can render samples unusable. The authors argue that careful sample handling is not a technical footnote but a determinant of whether an immunomonitoring program generates trustworthy data, and they call for cell fitness criteria and standardized operating procedures to be adopted broadly.

The review’s central message is one of complementarity rather than competition. Functional assays such as ELISPOT and intracellular cytokine staining answer whether T cells respond and what they secrete; activation-induced marker assays capture viable responding cells across the full repertoire; multimer staining delivers phenotype and frequency with single-epitope resolution; and sequencing connects specificity with clonal architecture and transcriptomic state. Harmonization efforts, from the MIATA reporting guidelines to international proficiency panels for ELISPOT, ICS and multimer assays, have progressively made results comparable across laboratories, a prerequisite for using immune biomarkers as endpoints in clinical trials. As personalized neoantigen vaccines, TCR-engineered cell therapies and mRNA platforms multiply, the authors conclude that thoughtful, multi-assay immunomonitoring, built on standardized sample handling and validated protocols, will remain the foundation for understanding and improving T cell-mediated immunity in the clinic.

Subject of Research: Comparative analysis of traditional and novel laboratory methods for quantifying and characterizing human antigen-specific T cells in immunomonitoring

Article Title: T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells

Article References: Lazzaro, S., Leroux-Roels, G., Janetzki, S., Salaun, B., Cook, L., Franke, K., Poschke, I., Bunse, L., Welters, M. J. P., Fehlings, M., Pattyn, S., Waerlop, G., Brix, L., Tubo, N. J., Molldrem, J. J., Denninger, V., van Esch, W. J. E., Kristensen, N. P., Mahnke, Y. D., … Koch, S. D. (2026). T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells. Nature Protocols. https://doi.org/10.1038/s41596-026-01453-8

Image Credits: AI Generated

DOI: 10.1038/s41596-026-01453-8

Keywords: T cells, immunomonitoring, ELISPOT, flow cytometry, peptide-MHC multimers, T cell receptor sequencing, single-cell multiomics, vaccines, cancer immunotherapy, assay harmonization, cytokines, antigen specificity